Regeneron stock pre-market at EUR 656.85: plus 0.12 percent
Published on 10/07/2026 at 07:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron stock was at EUR 656.85 pre-market on October 7, 2026, at 7:53 a.m. CEST, up 0.12 percent versus the EUR 656.05 prior close at Lang & Schwarz on October 6, 2026.
Pre-market quote
The Lang & Schwarz bid was EUR 653.60 and the ask was EUR 660.10. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Regeneron stock.
Expanded Sanofi alliance
In a company release dated October 1, 2026, Regeneron Pharmaceuticals, Inc. and Sanofi announced an expanded antibody collaboration. The agreement covers four new long-acting antibodies, including Regeneron's REGN20423, which is in a Phase 1 trial for atopic dermatitis. Regeneron said it will receive USD 1 billion upfront and may receive up to an additional USD 7 billion in development, regulatory and commercial milestones. The companies will share development and commercialization costs and split potential future profits equally.
COURAGE trial findings
In a separate company release dated October 1, 2026, Regeneron reported Phase 2 COURAGE results for trevogrumab in combination with semaglutide. At 52 weeks, the 25-milligram trevogrumab group showed 71.80 percent muscle preservation relative to placebo plus semaglutide in an MRI analysis. Regeneron said the lower doses were generally well tolerated in the trial.
